




=> d l1  
 L1 HAS NO ANSWERS  
 L1 STR



G1 C,NH  
 G2 [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 11:29:08 ON 29 DEC 2005)

FILE 'REGISTRY' ENTERED AT 11:29:14 ON 29 DEC 2005

L1 STRUCTURE UPLOADED  
 L2 9 S L1  
 L3 160 S L1 FUL  
 L4 159 S L3 AND CAPLUS/LC  
 L5 1 S L3 NOT L4  
 L6 0 S L3 AND REF.CAPLUS>20

FILE 'CAPLUS' ENTERED AT 11:30:19 ON 29 DEC 2005

L7 11 S L3

888  
 12/29/05

L7 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:49499 CAPLUS

DOCUMENT NUMBER: 138:233955

TITLE: Co-crystallization of Staphylococcus aureus peptide deformylase (PDF) with potent inhibitors

AUTHOR(S): Harris, M. S.; Bock, J. H.; Choi, G.; Cialdella, J. S.; Curry, K. A.; Deibel, M. R., Jr.; Jacobsen, E. J.; Marshall, V. P.; Murray, R. W., Jr.; Vosters, A. F.; Wolfe, C. L.; Yem, A. W.; Baldwin, E. T.

CORPORATE SOURCE: Structural Analytical and Medicinal Chemistry, Pharmacia Corporation, Kalamazoo, MI, 49007, USA

SOURCE: Acta Crystallographica, Section D: Biological Crystallography (2002), D58(12), 2153-2156  
CODEN: ABCRE6; ISSN: 0907-4449

PUBLISHER: Blackwell Munksgaard

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In bacteria the biosynthesis of all nascent polypeptides begins with N-formylmethionine. The post-translational removal of the N-formyl group is carried out by peptide deformylase (PDF). Processing of the N-formyl group from critical bacterial proteins is required for cell survival. This formylation/deformylation cycle is unique to eubacteria and is not utilized in eucaryotic cytosolic protein biosynthesis. Thus, inhibition of PDF would halt bacterial growth, spare host cell-function, and would be a novel mechanism for a new class of antibiotic. Diffraction-quality Se-met crystals of *S. aureus* PDF were prepared that belong to space group C2221 with unit cell parameters of  $a = 94.1$   $b = 121.9$   $c = 47.6$  Å. Multiple anomalous dispersion data were collected at the Advanced Photon Source 17-ID beamline and used to solve the PDF structure to 1.9 Å resolution. Crystals were also prepared with three PDF inhibitors: thiorphan, actinonin and PNU-172550. The thiorphan and actinonin co-crystals belong to space group C2221 with similar unit-cell dimensions. Repeated attempts to generate a complex structure of PDF with PNU-172550 from the orthorhombic space group were unsuccessful. Crystallization screening identified

an alternate C2 crystal form with unit-cell dimensions of  $a = 93.4$   $b = 42.5$   $c = 104.1$  Å,  $\beta = 93^\circ$ .

IT 196950-64-8D, PNU 172550, complexes with peptide deformylase


RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(crystal structure of Staphylococcus aureus peptide deformylase with potent inhibitors)

RN 196950-64-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ -(phenylmethyl)-, ( $\alpha$ S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:49499 CAPLUS

DOCUMENT NUMBER: 138:233955

TITLE: Co-crystallization of Staphylococcus aureus peptide deformylase (PDF) with potent inhibitors

AUTHOR(S): Harris, M. S.; Bock, J. H.; Choi, G.; Cialdella, J. S.; Curry, K. A.; Deibel, M. R., Jr.; Jacobsen, E. J.; Marshall, V. P.; Murray, R. W., Jr.; Vosters, A. F.; Wolfe, C. L.; Yem, A. W.; Baldwin, E. T.

CORPORATE SOURCE: Structural Analytical and Medicinal Chemistry, Pharmacia Corporation, Kalamazoo, MI, 49007, USA

SOURCE: Acta Crystallographica, Section D: Biological Crystallography (2002), D58(12), 2153-2156  
CODEN: ABCRE6; ISSN: 0907-4449

PUBLISHER: Blackwell Munksgaard

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In bacteria the biosynthesis of all nascent polypeptides begins with N-formylmethionine. The post-translational removal of the N-formyl group is carried out by peptide deformylase (PDF). Processing of the N-formyl group from critical bacterial proteins is required for cell survival. This formylation/deformylation cycle is unique to eubacteria and is not utilized in eucaryotic cytosolic protein biosynthesis. Thus, inhibition of PDF would halt bacterial growth, spare host cell-function, and would be a novel mechanism for a new class of antibiotic. Diffraction-quality Se-met crystals of S. aureus PDF were prepared that belong to space group C2221 with unit cell parameters of  $a = 94.1$   $b = 121.9$   $c = 47.6$  Å. Multiple anomalous dispersion data were collected at the Advanced Photon Source 17-ID beamline and used to solve the PDF structure to 1.9 Å resolution. Crystals were also prepared with three PDF inhibitors: thiorphan, actinonin and PNU-172550. The thiorphan and actinonin co-crystals belong to space group C2221 with similar unit-cell dimensions. Repeated attempts to generate a complex structure of PDF with PNU-172550 from the orthorhombic space group were unsuccessful. Crystallization screening identified

an alternate C2 crystal form with unit-cell dimensions of  $a = 93.4$   $b = 42.5$   $c = 104.1$  Å,  $\beta = 93^\circ$ .

IT 196950-64-8D, PNU 172550, complexes with peptide deformylase  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)


(crystal structure of Staphylococcus aureus peptide deformylase with potent inhibitors)

RN 196950-64-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ -(phenylmethyl)-, ( $\alpha$ S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:539676 CAPLUS

DOCUMENT NUMBER: 137:93693

TITLE: Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-  
substituted pyrrolidineacetamides and  
piperidineacetamides and related compounds as MMP,  
TNF, and/or aggrecanase inhibitors

INVENTOR(S): Chen, Xiao-Tao; Xue, Chu-Biao

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 151 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055516	A2	20020718	WO 2002-US761	20020109
WO 2002055516	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434205	AA	20020718	CA 2002-2434205	20020109
US 2002137734	A1	20020926	US 2002-43627	20020109
US 6825215	B2	20041130		
EP 1355901	A2	20031029	EP 2002-714734	20020109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-260952P	P 20010111
			WO 2002-US761	W 20020109
OTHER SOURCE(S):			MARPAT 137:93693	
GI				



AB Title compds. I [wherein A = COR<sub>5</sub>, CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H, CO<sub>2</sub>R<sub>6</sub>, CONHOH, CONHOR<sub>5</sub>, CONHOR<sub>6</sub>, N(OH)CHO, N(OH)COR<sub>5</sub>, SH, CH<sub>2</sub>SH, SONHRA, SN<sub>2</sub>H<sub>2</sub>RA, PO<sub>3</sub>H<sub>2</sub>, or PO(OH)NHRA; ring B = 3-10 membered (hetero)cyclyl; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl), CO, CO<sub>2</sub>, OCO, CONH, NHCO, OCO<sub>2</sub>, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SOO-2, or CO; Z<sub>a</sub> = (un)substituted (hetero)cyclyl; R<sub>1a</sub> and R<sub>1b</sub> = independently H, alkyl, Ph, PhCH<sub>2</sub>, CH<sub>2</sub>OR<sub>3</sub>, or (un)substituted CH<sub>2</sub>NH<sub>2</sub>; or CR<sub>1a</sub>R<sub>1b</sub> = (hetero)cyclyl; R<sub>2</sub> = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R<sub>2a</sub> and R<sub>2b</sub> = independently H, alkyl, Ph, PhCH<sub>2</sub>, CH<sub>2</sub>OR<sub>3</sub>, or (un)substituted CH<sub>2</sub>NH<sub>2</sub>; or CR<sub>2a</sub>R<sub>2b</sub> = heterocyclyl; R<sub>3</sub> = Q<sub>1</sub> or (un)substituted alkylene-Q<sub>1</sub>, alkenylene-Q<sub>1</sub>, or alkynylene-Q<sub>1</sub>, Q<sub>1</sub>-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R<sub>3</sub>)<sub>2</sub> = (un)substituted (hetero)cyclyl; Q<sub>1</sub> = H or (un)substituted Ph, naphthyl, or heteroaryl; R<sub>a</sub> = H, alkyl, Ph, or PhCH<sub>2</sub>; p = 0-2; R<sub>5</sub> = (un)substituted alkyl; R<sub>6</sub> = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the N-hydroxy-2-(quinolinylmethoxyphenylsulfonyl methyl)-2-pyrrolidineacetamide II•2CF<sub>3</sub>CO<sub>2</sub>H was prepared in twelve steps starting with the esterification of N-Boc-proline using MeI and K<sub>2</sub>CO<sub>3</sub> in acetone. Key steps include the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds. exhibited K<sub>i</sub> values of ≤ 10 μM against MMP-1, 2, 3, 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).

IT 441773-44-0P 441773-45-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(MMP, TNF, and/or aggrecanase inhibitor; preparation of

(quinolinylmethoxyphenylsulfonylmethyl)-substituted  
pyrrolidineacetamides and piperidineacetamides and related compds. as  
MMP, TNF, and/or aggrecanase inhibitors)

RN 441773-44-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 441773-45-1 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo-, mono(trifluoroacetate)  
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-44-0

CMF C25 H27 N3 O6 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:275960 CAPLUS  
 DOCUMENT NUMBER: 136:310184  
 TITLE: Preparation of hydroxamic acid peptide deformylase inhibitors as antibacterial agents  
 INVENTOR(S): Chong, Lee; Frechette, Roger; Scott, Carole; Tester, Richard; Smith, Whitney; Chiba, Katsumi; Sakamoto, Masatoshi; Gluchowski, Charles  
 PATENT ASSIGNEE(S): Questcor Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 171 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028829	A2	20020411	WO 2001-US29926	20010924
WO 2002028829	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030385	A5	20020415	AU 2002-30385	20010924
PRIORITY APPLN. INFO.:			US 2000-234967P	P 20000925
			US 2001-761850	A 20010118
			WO 2001-US29926	W 20010924
OTHER SOURCE(S):		MARPAT 136:310184		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Hydroxamic acid derivs. of peptides and peptidomimetics of formulas I, II, and III [wherein Z = NHOH or ORa; Ra = alkyl or a biocleavable moiety; X = CO or SO<sub>2</sub>; Y = (un)substituted heteroalkyl or heterocyclyl; R1 = (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or heteroalkyl; R2R3 = 4-7 membered (un)substituted heterocycle; R2R4 = ring formed through a CH<sub>2</sub>CH<sub>2</sub> linkage; or R2 = Me; or R3 = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; or R4 = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; R5 and R6 = independently H, NO<sub>2</sub>, NH<sub>2</sub>, NHOH, NHOCH<sub>3</sub>, NHOCH<sub>2</sub>CH<sub>3</sub>, or (un)substituted CH<sub>2</sub>NH-(hetero)alkyl or CH<sub>2</sub>NH-heterocyclyl; one of R7 or R8 = CHR<sub>10</sub>CONHOH; one of R7 or R8 = (un)substituted (hetero)alkyl, (alkyl)heterocyclyl, or alkylaryl; R9 and R10 = independently H or (un)substituted (hetero)alkyl, (alkyl)heterocyclyl, or alkylaryl] were prepared as peptide deformylase (Fe-PDF) inhibitors for treating various bacterial infections. For example, 3-pyrrolidinol was added to tert-Bu (R)-(2-pentyl)succinate mono(N-hydroxysuccinimide) ester to give the amide (68%). Treatment with 20% TFA/DCM, followed by MeOH, benzene, and TMSN<sub>2</sub> in hexanes, to afford the Me ester (90%). The

pyrrolidinol was coupled with 4-methoxyphenylisocyanate and the ester converted to the hydroxamic acid (IV) using  $\text{NH}_2\text{OH}\cdot\text{HCl}$ . The latter inhibited *E. coli* Fe-PDF with  $\text{IC}_{50}$  of 9 nM and showed selectivity for Fe-PDF vs. thermolysin with a selectivity index of 30,000. Thus, I, II, and III are useful as antibiotics against a broad range of infectious disease in animals and humans.

IT 409130-54-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide deformylase inhibitor; preparation of hydroxamic acid derivs. of peptides and peptidomimetics as peptide deformylase inhibitors for treatment of infectious diseases)

RN 409130-54-7 CAPLUS

CN 3-Pyrrolidineacetamide, 3-butyl-N-hydroxy-1-[(1S)-2-methyl-1-(1-pyrrolidinylcarbonyl)propyl]-2-oxo-, (3S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L7 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:98031 CAPLUS  
 DOCUMENT NUMBER: 128:154002  
 TITLE: Preparation of 2-oxopyrrolidine-3-acetohydroxamic  
 acids and analogs as matrix metalloproteinase  
 inhibitors  
 INVENTOR(S): Jacobsen, E. Jon  
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Co., USA  
 SOURCE: U.S., 87 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5712300	A	19980127	US 1997-811821	19970304
PRIORITY APPLN. INFO.:			US 1997-811821	19970304
OTHER SOURCE(S):	MARPAT	128:154002		

GI



AB Title compds. [I; R = CR<sub>2</sub>R<sub>10</sub>CONHOH; R<sub>1</sub> = H, (un)substituted alkyl, aryl, etc.; R<sub>2</sub> = H, alkyl(amino), alkoxy, etc.; R<sub>3</sub> = H, alkyl, aryl(alkyl), etc.; R<sub>4</sub> = H or (un)substituted carbamoyl; R<sub>10</sub> = H, OH, alkoxy, (alkyl)amino, etc.; Z<sub>1</sub> = CH<sub>2</sub>, CO, (alkyl)imino, etc.; Z<sub>2</sub> = CH<sub>2</sub>, (alkyl)imino, etc.] were prepared Thus,  $\gamma$ -butyrolactone was cyclocondensed with PhCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub> and the Me<sub>2</sub>CHCH<sub>2</sub>I-alkylated product condensed with BrCH<sub>2</sub>CO<sub>2</sub>CMe<sub>3</sub> to give, in 2 addnl. steps, title compound II. Data for biol. activity of I were given.


IT 196949-33-4P 196949-35-6P 196949-82-3P  
 196949-86-7P 196949-93-6P 196950-05-7P  
 196950-12-6P 196950-15-9P 196950-17-1P  
 196950-20-6P 196950-23-9P 196950-27-3P  
 196950-32-0P 196950-35-3P 196950-38-6P  
 196950-40-0P 196950-43-3P 196950-46-6P  
 196950-48-8P 196950-51-3P 196950-54-6P  
 196950-55-7P 196950-57-9P 196950-60-4P  
 196950-62-6P 196950-64-8P 196950-67-1P  
 196950-68-2P 196950-69-3P 196950-70-6P  
 196950-74-0P 196950-76-2P 196950-78-4P  
 196951-67-4P 196951-72-1P 196951-76-5P  
 196951-80-1P 196951-84-5P 196951-86-7P  
 196951-89-0P 196951-91-4P 196951-93-6P



196951-96-9P 196952-00-8P 196952-03-1P  
 196952-06-4P 196952-09-7P 196952-11-1P  
 196952-15-5P 196952-17-7P 196952-19-9P  
 196952-23-5P 196952-29-1P 196952-34-8P  
 196952-39-3P 196952-45-1P 196952-51-9P  
 196952-57-5P 196952-63-3P 196952-69-9P  
 196952-73-5P 196952-77-9P 196952-80-4P  
 196952-83-7P 196952-87-1P 196952-90-6P  
 196952-92-8P 196952-94-0P 196952-97-3P  
 196953-01-2P 196953-03-4P 196953-05-6P  
 196953-07-8P 196953-09-0P 196953-11-4P  
 196953-13-6P 196953-15-8P 196953-17-0P  
 196953-19-2P 196953-21-6P 196953-24-9P  
 196953-26-1P 196953-28-3P 196953-31-8P  
 196953-33-0P 196953-34-1P 196953-37-4P  
 196953-41-0P 196953-45-4P 196953-49-8P  
 196953-52-3P 196953-55-6P 196953-57-8P  
 196953-61-4P 196953-63-6P 196953-66-9P  
 196953-69-2P 196953-72-7P 196953-74-9P  
 196953-76-1P 196953-78-3P 196953-81-8P  
 196953-85-2P 196953-88-5P 196953-92-1P  
 196953-96-5P 196953-99-8P 196954-01-5P  
 196954-04-8P 196954-06-0P 196954-09-3P  
 196954-12-8P 196954-15-1P 196954-18-4P  
 196954-20-8P 196954-22-0P 196954-24-2P  
 196954-26-4P 196954-28-6P 196954-30-0P  
 196954-32-2P 196954-34-4P 196954-36-6P  
 196954-38-8P 196954-40-2P 196954-42-4P  
 196954-44-6P 196954-47-9P 196954-50-4P  
 196954-53-7P 196954-55-9P 196954-57-1P  
 196954-59-3P 196954-61-7P 202531-63-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2-oxopyrrolidine-3-acetohydroxamic acids and analogs as matrix metalloproteinase inhibitors)

RN 196949-33-4 CAPLUS  
 CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 196949-35-6 CAPLUS  
 CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

9 gll


10/507,510

Page 3




RN 196949-82-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-  
(9CI) (CA INDEX NAME)




RN 196949-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-  
 $\alpha$ 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196949-93-6 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-  
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196950-05-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-12-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-(2-phenylethyl)-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-15-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-α1,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 196950-17-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(cyclohexylmethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-20-6 CAPLUS


CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(3-methylbutyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 196950-23-9 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-27-3 CAPLUS


CN 4-Imidazolidineacetamide, N-hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-32-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-35-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-(2-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-38-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-40-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 196950-43-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-[1-(phenylmethyl)-4-piperidiny]-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196950-46-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-4-piperidiny-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-48-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-(4-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-51-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-[(4-fluorophenyl)methyl]-N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-54-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-



$\alpha$ 1-(2-phenylethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-55-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(2-phenylethyl)-N1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-57-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1,3-bis(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-60-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-62-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-64-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ -(phenylmethyl)-, ( $\alpha$ S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-67-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-N1-[2-(4-morpholinyl)ethyl]-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-68-2 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 196950-69-3 CAPLUS

CN 3-Pyrrolidineacetamide, 1-[2-(3,5-dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

[3S-[1[R\*(cis)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-70-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-74-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-76-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-78-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-67-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-72-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-76-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-80-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-84-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-(4-fluorophenyl)-α-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196951-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-α-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196951-89-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-91-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-93-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-96-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-00-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-03-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-06-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-09-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-11-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-15-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-17-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-19-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




9 of 11

10/507,510

Page 24


RN 196952-23-5 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-29-1 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196952-34-8 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-39-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-45-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196952-51-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-57-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-63-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-69-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-73-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-77-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-80-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-83-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-87-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-90-6 CAPLUS


CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-92-8 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-94-0 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196952-97-3 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-01-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-03-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-05-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-07-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-09-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-11-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-13-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-15-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-17-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-19-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-  
α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-21-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4-  
fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-24-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-26-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-28-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-31-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-33-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-34-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-37-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-41-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-45-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 196953-49-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-52-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196953-55-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-57-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-61-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-63-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-66-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-69-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-72-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)- $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-74-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-76-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-78-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-81-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-85-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-88-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-92-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-96-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-99-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-01-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-04-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluorophenyl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)] - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-06-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-09-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-12-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-15-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-18-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-20-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-22-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-24-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)] - (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-26-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-28-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-30-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-32-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-heptyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-34-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196954-36-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-38-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-40-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-42-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-44-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-47-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-50-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-53-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-55-9 CAPLUS


CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-57-1 CAPLUS  
CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-59-3 CAPLUS  
CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196954-61-7 CAPLUS  
CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 202531-63-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[2-(benzoylamino)ethyl]-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:



8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:618069 CAPLUS  
 DOCUMENT NUMBER: 127:293126  
 TITLE: Pyrrolidinone hydroxamic acid derivatives for use in  
 the treatment of diseases related to connective tissue  
 degradation  
 INVENTOR(S): Jacobsen, E. Jon  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Jacobsen, E. Jon  
 SOURCE: PCT Int. Appl., 207 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732846	A1	19970912	WO 1997-US2568	19970303
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 448172	B	20010801	TW 1997-86102076	19970221
CA 2244903	AA	19970912	CA 1997-2244903	19970303
AU 9720525	A1	19970922	AU 1997-20525	19970303
AU 707180	B2	19990701		
EP 898562	A1	19990303	EP 1997-908674	19970303
EP 898562	B1	20030122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1210517	A	19990310	CN 1997-192171	19970303
BR 9707947	A	19990727	BR 1997-7947	19970303
NZ 330922	A	20000128	NZ 1997-330922	19970303
JP 2000506163	T2	20000523	JP 1997-531784	19970303
RU 2168497	C2	20010610	RU 1998-118372	19970303
AT 231490	E	20030215	AT 1997-908674	19970303
PT 898562	T	20030630	PT 1997-908674	19970303
ES 2191823	T3	20030916	ES 1997-908674	19970303
ZA 9701902	A	19980907	ZA 1997-1902	19970305
NO 9804112	A	19981106	NO 1998-4112	19980907
NO 312956	B1	20020722		
PRIORITY APPLN. INFO.:			US 1996-13098P	P 19960308
			WO 1997-US2568	W 19970303
OTHER SOURCE(S):				
GI				
MARPAT 127:293126				

1084



- AB The invention provides novel hydroxamic acid derivs. I and their pharmaceutically acceptable salts [wherein X = CH<sub>2</sub>, NR<sub>5</sub>, CO; Y = CH<sub>2</sub>, NR<sub>5</sub>; provided that Y = CH<sub>2</sub> when X = NR<sub>5</sub>; R<sup>1</sup> = H, alkyl, (CH<sub>2</sub>)<sub>i</sub>-Ar, (CH<sub>2</sub>)<sub>i</sub>OR<sub>5</sub>, (CH<sub>2</sub>)<sub>i</sub>-Het, etc.; R<sup>2</sup> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>OR<sub>5</sub>, NHR<sub>5</sub>, (CH<sub>2</sub>)<sub>j</sub>NR<sub>6</sub>R<sub>7</sub>, etc; R<sup>3</sup> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Het, (CH<sub>2</sub>)<sub>j</sub>-cycloalkyl, CONHR<sub>5</sub>; R<sup>4</sup> = H, CONHR<sub>5</sub>, CONR<sub>6</sub>R<sub>7</sub>, other derivs. of CONH<sub>2</sub>, etc.; R<sub>5</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Ar-Ar, (CH<sub>2</sub>)<sub>j</sub>-Ar-(CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Het, (CH<sub>2</sub>)<sub>j</sub>-cycloalkyl; R<sub>6</sub>, R<sub>7</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, Q; or NR<sub>6</sub>R<sub>7</sub> = (optionally alkyl-substituted) azetidiny, pyrrolidinyl, piperazinyl, piperidinyl, or morpholinyl; R<sup>10</sup> = H, OH, OR<sub>5</sub>, NHR<sub>5</sub>, (CH<sub>2</sub>)<sub>j</sub>OR<sub>5</sub>; Ar = (un)substituted Ph; Het = 5- or 6-membered N/O/S heterocycle; Q = saturated 5- or 6-membered N/O/S heterocycle; i = 1-6, j = 0-4]. I inhibit various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, and are useful for the treatment of matrix metallo-endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal, dermal, and gastric ulceration, and other diseases related to connective tissue degradation. For instance, 1-(2-phenylethyl)-2-pyrrolidinone underwent a sequence of lithiation with LDA and C-alkylation with iso-BuI (99%), a second alkylation with BrCH<sub>2</sub>COBu-tert (68%), saponification with CF<sub>3</sub>CO<sub>2</sub>H (92%), and hydroxamidation with NH<sub>2</sub>OH.HCl using EDC and HOBT (31%), to give title compound II. The title compound III inhibited matrix metalloproteinases in vitro with K<sub>i</sub> (μM) as follows: stromelysin 0.0105, gelatinase 0.00106, and collagenase 0.00069.
- IT 196949-33-4P 196949-35-6P 196949-82-3P  
 196949-86-7P 196949-93-6P 196950-05-7P  
 196950-12-6P 196950-15-9P 196950-17-1P  
 196950-20-6P 196950-23-9P 196950-27-3P




196950-32-0P 196950-35-3P 196950-38-6P  
 196950-40-0P 196950-43-3P 196950-46-6P  
 196950-48-8P 196950-51-3P 196950-54-6P  
 196950-55-7P 196950-57-9P 196950-60-4P  
 196950-62-6P 196950-64-8P 196950-67-1P  
 196950-68-2P 196950-69-3P 196950-70-6P  
 196950-74-0P 196950-76-2P 196950-78-4P  
 196951-67-4P 196951-72-1P 196951-76-5P  
 196951-80-1P 196951-84-5P 196951-86-7P  
 196951-89-0P 196951-91-4P 196951-93-6P  
 196951-96-9P 196952-00-8P 196952-03-1P  
 196952-06-4P 196952-09-7P 196952-11-1P  
 196952-15-5P 196952-17-7P 196952-19-9P  
 196952-23-5P 196952-29-1P 196952-34-8P  
 196952-39-3P 196952-45-1P 196952-51-9P  
 196952-57-5P 196952-63-3P 196952-69-9P  
 196952-73-5P 196952-77-9P 196952-80-4P  
 196952-83-7P 196952-87-1P 196952-90-6P  
 196952-92-8P 196952-94-0P 196952-97-3P  
 196953-01-2P 196953-03-4P 196953-05-6P  
 196953-07-8P 196953-09-0P 196953-11-4P  
 196953-13-6P 196953-15-8P 196953-17-0P  
 196953-19-2P 196953-21-6P 196953-24-9P  
 196953-26-1P 196953-28-3P 196953-31-8P  
 196953-33-0P 196953-34-1P 196953-37-4P  
 196953-41-0P 196953-45-4P 196953-49-8P  
 196953-52-3P 196953-55-6P 196953-57-8P  
 196953-61-4P 196953-63-6P 196953-66-9P  
 196953-69-2P 196953-72-7P 196953-74-9P  
 196953-76-1P 196953-78-3P 196953-81-8P  
 196953-85-2P 196953-88-5P 196953-92-1P  
 196953-96-5P 196953-99-8P 196954-01-5P  
 196954-04-8P 196954-06-0P 196954-09-3P  
 196954-12-8P 196954-15-1P 196954-18-4P  
 196954-20-8P 196954-22-0P 196954-24-2P  
 196954-26-4P 196954-28-6P 196954-30-0P  
 196954-32-2P 196954-34-4P 196954-36-6P  
 196954-38-8P 196954-40-2P 196954-42-4P  
 196954-44-6P 196954-47-9P 196954-50-4P  
 196954-53-7P 196954-55-9P 196954-57-1P  
 196954-59-3P 196954-61-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidinone hydroxamic acid derivs. for treatment of connective tissue degradation diseases)

RN 196949-33-4 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196949-35-6 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196949-82-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 196949-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196949-93-6 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196950-05-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-12-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-(2-phenylethyl)- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-15-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl- $\alpha$ 1,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 196950-17-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(cyclohexylmethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196950-20-6 CAPLUS


CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(3-methylbutyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10811


10/507,510

Page 7




RN 196950-23-9 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-27-3 CAPLUS


CN 4-Imidazolidineacetamide, N-hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-32-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-)..



RN 196950-35-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-(2-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-38-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-40-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 196950-43-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-[1-(phenylmethyl)-4-piperidinyl]-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196950-46-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-4-piperidinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-48-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-(4-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-51-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-[(4-fluorophenyl)methyl]-N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-54-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-



$\alpha$ 1-(2-phenylethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-55-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(2-phenylethyl)-N1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-57-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1,3-bis(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10 of 11

RN 196950-60-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-62-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-64-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ -(phenylmethyl)-, ( $\alpha$ S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-67-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-N1-[2-(4-morpholinyl)ethyl]-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-68-2 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 196950-69-3 CAPLUS

CN 3-Pyrrolidineacetamide, 1-[2-(3,5-dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-,

[3S-[1[R\*(cis)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-70-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-74-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-76-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-78-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-67-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-72-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-76-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-80-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-84-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196951-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196951-89-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-91-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196951-93-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-96-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-00-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-03-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-06-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-09-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-11-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-15-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-17-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-19-9 CAPLUS


CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-23-5 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196952-29-1 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-34-8 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10 of 11



RN 196952-39-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-45-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196952-51-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-57-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-63-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-69-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-73-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-77-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-80-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-83-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-87-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-90-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10 of 11

RN 196952-92-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-94-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-97-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-01-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-03-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-05-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-07-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-09-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-11-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-13-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-15-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-17-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-19-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-  
α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-21-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4-  
fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-24-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-26-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-28-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-31-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-33-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-34-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-37-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-41-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-45-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)] - (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 196953-49-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-52-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196953-55-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-57-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-61-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-63-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-66-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-69-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-72-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-74-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-76-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10 of 11



RN 196953-78-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-81-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-85-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-88-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-92-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-96-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-99-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-01-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-04-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-06-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-09-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-12-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-15-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-18-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-20-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 196954-22-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


10811



RN 196954-24-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-26-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-28-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-30-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-32-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-34-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196954-36-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-38-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-40-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-42-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-44-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-47-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-50-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-53-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-55-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10 of 11


RN 196954-57-1 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-59-3 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 196954-61-7 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:618069 CAPLUS  
 DOCUMENT NUMBER: 127:293126  
 TITLE: Pyrrolidinone hydroxamic acid derivatives for use in  
 the treatment of diseases related to connective tissue  
 degradation  
 INVENTOR(S): Jacobsen, E. Jon  
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Jacobsen, E. Jon  
 SOURCE: PCT Int. Appl., 207 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732846	A1	19970912	WO 1997-US2568	19970303
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 448172	B	20010801	TW 1997-86102076	19970221
CA 2244903	AA	19970912	CA 1997-2244903	19970303
AU 9720525	A1	19970922	AU 1997-20525	19970303
AU 707180	B2	19990701		
EP 898562	A1	19990303	EP 1997-908674	19970303
EP 898562	B1	20030122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1210517	A	19990310	CN 1997-192171	19970303
BR 9707947	A	19990727	BR 1997-7947	19970303
NZ 330922	A	20000128	NZ 1997-330922	19970303
JP 2000506163	T2	20000523	JP 1997-531784	19970303
RU 2168497	C2	20010610	RU 1998-118372	19970303
AT 231490	E	20030215	AT 1997-908674	19970303
PT 898562	T	20030630	PT 1997-908674	19970303
ES 2191823	T3	20030916	ES 1997-908674	19970303
ZA 9701902	A	19980907	ZA 1997-1902	19970305
NO 9804112	A	19981106	NO 1998-4112	19980907
NO 312956	B1	20020722		
PRIORITY APPLN. INFO.:			US 1996-13098P	P 19960308
			WO 1997-US2568	W 19970303
OTHER SOURCE(S):			MARPAT 127:293126	
GI				



AB The invention provides novel hydroxamic acid derivs. I and their pharmaceutically acceptable salts [wherein X = CH<sub>2</sub>, NR<sub>5</sub>, CO; Y = CH<sub>2</sub>, NR<sub>5</sub>; provided that Y = CH<sub>2</sub> when X = NR<sub>5</sub>; R<sub>1</sub> = H, alkyl, (CH<sub>2</sub>)<sub>i</sub>-Ar, (CH<sub>2</sub>)<sub>i</sub>OR<sub>5</sub>, (CH<sub>2</sub>)<sub>i</sub>-Het, etc.; R<sub>2</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>OR<sub>5</sub>, NHR<sub>5</sub>, (CH<sub>2</sub>)<sub>j</sub>NR<sub>6</sub>R<sub>7</sub>, etc; R<sub>3</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Het, (CH<sub>2</sub>)<sub>j</sub>-cycloalkyl, CONHR<sub>5</sub>; R<sub>4</sub> = H, CONHR<sub>5</sub>, CONR<sub>6</sub>R<sub>7</sub>, other derivs. of CONH<sub>2</sub>, etc.; R<sub>5</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Ar-Ar, (CH<sub>2</sub>)<sub>j</sub>-Ar-(CH<sub>2</sub>)<sub>j</sub>-Ar, (CH<sub>2</sub>)<sub>j</sub>-Het, (CH<sub>2</sub>)-cycloalkyl; R<sub>6</sub>, R<sub>7</sub> = H, alkyl, (CH<sub>2</sub>)<sub>j</sub>-Ar, Q; or NR<sub>6</sub>R<sub>7</sub> = (optionally alkyl-substituted) azetidiny, pyrrolidinyl, piperazinyl, piperidinyl, or morpholinyl; R<sub>10</sub> = H, OH, OR<sub>5</sub>, NHR<sub>5</sub>, (CH<sub>2</sub>)<sub>j</sub>OR<sub>5</sub>; Ar = (un)substituted Ph; Het = 5- or 6-membered N/O/S heterocycle; Q = saturated 5- or 6-membered N/O/S heterocycle; i = 1-6, j = 0-4]. I inhibit various enzymes from the matrix metalloproteinase family, including collagenase, stromelysin, and gelatinase, and are useful for the treatment of matrix metallo-endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal, dermal, and gastric ulceration, and other diseases related to connective tissue degradation. For instance, 1-(2-phenylethyl)-2-pyrrolidinone underwent a sequence of lithiation with LDA and C-alkylation with iso-BuI (99%), a second alkylation with BrCH<sub>2</sub>COBu-tert (68%), saponification with CF<sub>3</sub>CO<sub>2</sub>H (92%), and hydroxamidation with NH<sub>2</sub>OH.HCl using EDC and HOBT (31%), to give title compound II. The title compound III inhibited matrix metalloproteinases in vitro with K<sub>i</sub> (μM) as follows: stromelysin 0.0105, gelatinase 0.00106, and collagenase 0.00069.

IT 196949-33-4P 196949-35-6P 196949-82-3P  
 196949-86-7P 196949-93-6P 196950-05-7P  
 196950-12-6P 196950-15-9P 196950-17-1P  
 196950-20-6P 196950-23-9P 196950-27-3P




196950-32-0P 196950-35-3P 196950-38-6P  
 196950-40-0P 196950-43-3P 196950-46-6P  
 196950-48-8P 196950-51-3P 196950-54-6P  
 196950-55-7P 196950-57-9P 196950-60-4P  
 196950-62-6P 196950-64-8P 196950-67-1P  
 196950-68-2P 196950-69-3P 196950-70-6P  
 196950-74-0P 196950-76-2P 196950-78-4P  
 196951-67-4P 196951-72-1P 196951-76-5P  
 196951-80-1P 196951-84-5P 196951-86-7P  
 196951-89-0P 196951-91-4P 196951-93-6P  
 196951-96-9P 196952-00-8P 196952-03-1P  
 196952-06-4P 196952-09-7P 196952-11-1P  
 196952-15-5P 196952-17-7P 196952-19-9P  
 196952-23-5P 196952-29-1P 196952-34-8P  
 196952-39-3P 196952-45-1P 196952-51-9P  
 196952-57-5P 196952-63-3P 196952-69-9P  
 196952-73-5P 196952-77-9P 196952-80-4P  
 196952-83-7P 196952-87-1P 196952-90-6P  
 196952-92-8P 196952-94-0P 196952-97-3P  
 196953-01-2P 196953-03-4P 196953-05-6P  
 196953-07-8P 196953-09-0P 196953-11-4P  
 196953-13-6P 196953-15-8P 196953-17-0P  
 196953-19-2P 196953-21-6P 196953-24-9P  
 196953-26-1P 196953-28-3P 196953-31-8P  
 196953-33-0P 196953-34-1P 196953-37-4P  
 196953-41-0P 196953-45-4P 196953-49-8P  
 196953-52-3P 196953-55-6P 196953-57-8P  
 196953-61-4P 196953-63-6P 196953-66-9P  
 196953-69-2P 196953-72-7P 196953-74-9P  
 196953-76-1P 196953-78-3P 196953-81-8P  
 196953-85-2P 196953-88-5P 196953-92-1P  
 196953-96-5P 196953-99-8P 196954-01-5P  
 196954-04-8P 196954-06-0P 196954-09-3P  
 196954-12-8P 196954-15-1P 196954-18-4P  
 196954-20-8P 196954-22-0P 196954-24-2P  
 196954-26-4P 196954-28-6P 196954-30-0P  
 196954-32-2P 196954-34-4P 196954-36-6P  
 196954-38-8P 196954-40-2P 196954-42-4P  
 196954-44-6P 196954-47-9P 196954-50-4P  
 196954-53-7P 196954-55-9P 196954-57-1P  
 196954-59-3P 196954-61-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidinone hydroxamic acid derivs. for treatment of connective tissue degradation diseases)

RN 196949-33-4 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196949-35-6 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196949-82-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-(9CI) (CA INDEX NAME)




RN 196949-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196949-93-6 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 196950-05-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-12-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-(2-phenylethyl)- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-15-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl- $\alpha$ 1,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 196950-17-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(cyclohexylmethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-20-6 CAPLUS


CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(3-methylbutyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 196950-23-9 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-27-3 CAPLUS


CN 4-Imidazolidineacetamide, N-hydroxy-4-(2-methylpropyl)-2,5-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 196950-32-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-35-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-(2-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-38-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-40-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 196950-43-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-[1-(phenylmethyl)-4-piperidiny]-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196950-46-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(phenylmethyl)-N1-4-piperidiny-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-48-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-(4-pyridinylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-51-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-[(4-fluorophenyl)methyl]-N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196950-54-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-



$\alpha$ 1-(2-phenylethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-55-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo- $\alpha$ 1-(2-phenylethyl)-N1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-57-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1,3-bis(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-60-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-62-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-64-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo- $\alpha$ -(phenylmethyl)-, ( $\alpha$ S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-67-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-N1-[2-(4-morpholinyl)ethyl]-2-oxo-α1-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-68-2 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-(2-methylpropyl)-1-[2-(4-morpholinyl)-2-oxo-1-(phenylmethyl)ethyl]-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 196950-69-3 CAPLUS

CN 3-Pyrrolidineacetamide, 1-[2-(3,5-dimethyl-1-piperazinyl)-2-oxo-1-(phenylmethyl)ethyl]-N-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

[3S-[1[R\*(cis)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-70-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-3-(2-methylpropyl)-2-oxo-α1-(phenylmethyl)-N1-2-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 196950-74-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-76-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196950-78-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-67-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-72-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-76-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-80-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-84-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196951-86-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196951-89-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-91-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-93-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196951-96-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-00-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-3-(2-methylpropyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-03-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-06-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-09-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-11-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-15-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-17-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-19-9 CAPLUS


CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-23-5 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-29-1 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196952-34-8 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(cyclopentylmethyl)- $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-39-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196952-45-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196952-51-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-57-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-63-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-(cyclopentylmethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-69-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-73-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-77-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-80-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-83-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N3-hydroxy-α1-(1-methylethyl)-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-87-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-90-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-92-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-94-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196952-97-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-01-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-03-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-05-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-07-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-09-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N3-hydroxy-2-oxo-3-(3-phenylpropyl)-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-11-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-13-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-15-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-17-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-19-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-  
α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-21-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4-  
fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 196953-24-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-26-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-28-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-31-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-33-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-34-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-37-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-41-0 CAPLUS


CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 196953-45-4 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4-fluorophenyl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-49-8 CAPLUS  
 CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-52-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196953-55-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-57-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-61-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-63-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-66-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-N1-cyclopropyl-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-69-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-72-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-74-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-(1,1-dimethylethyl)-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-76-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-78-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-cyclopropyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-81-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-85-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-88-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-(3-[1,1'-biphenyl]-4-ylpropyl)-α1-cyclohexyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196953-92-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196953-96-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196953-99-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-α1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-01-5 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-α1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-04-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-[3-(4'-fluorophenyl)propyl]-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-06-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluorophenyl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-09-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-12-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-15-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-18-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-(1,1-dimethylethyl)-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-20-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-22-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-24-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 196954-26-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N1-(4-fluorophenyl)-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-28-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-[3-(4'-fluoro[1,1'-biphenyl]-4-yl)propyl]-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-30-0 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy-N1-methyl- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-32-2 CAPLUS.

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl-3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196954-34-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 196954-36-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-38-8 CAPLUS

CN 1,3-Pyrrolidinediacetamide, 3-heptyl-N3-hydroxy- $\alpha$ 1-(1-methylethyl)-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-40-2 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-42-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide, N1-cyclopropyl- $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-44-6 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-47-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-50-4 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-(1,1-dimethylethyl)-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-53-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-3-heptyl-N3-hydroxy-N1-methyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-55-9 CAPLUS

CN 1,3-Pyrrolidinediacetamide, α1-cyclohexyl-N1-cyclopropyl-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-57-1 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-phenyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-59-3 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-N1-(4-fluorophenyl)-3-heptyl-N3-hydroxy-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196954-61-7 CAPLUS

CN 1,3-Pyrrolidinediacetamide,  $\alpha$ 1-cyclohexyl-3-heptyl-N3-hydroxy-2-oxo-N1-4-pyridinyl-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:275960 CAPLUS  
 DOCUMENT NUMBER: 136:310184  
 TITLE: Preparation of hydroxamic acid peptide deformylase inhibitors as antibacterial agents  
 INVENTOR(S): Chong, Lee; Frechette, Roger; Scott, Carole; Tester, Richard; Smith, Whitney; Chiba, Katsumi; Sakamoto, Masatoshi; Gluchowski, Charles  
 PATENT ASSIGNEE(S): Questcor Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 171 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028829	A2	20020411	WO 2001-US29926	20010924
WO 2002028829	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030385	A5	20020415	AU 2002-30385	20010924
PRIORITY APPLN. INFO.:			US 2000-234967P	P 20000925
			US 2001-761850	A 20010118
			WO 2001-US29926	W 20010924
OTHER SOURCE(S):			MARPAT 136:310184	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Hydroxamic acid derivs. of peptides and peptidomimetics of formulas I, II, and III [wherein Z = NHOH or ORa; Ra = alkyl or a biocleavable moiety; X = CO or SO<sub>2</sub>; Y = (un)substituted heteroalkyl or heterocyclyl; R<sub>1</sub> = (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or heteroalkyl; R<sub>2</sub>R<sub>3</sub> = 4-7 membered (un)substituted heterocycle; R<sub>2</sub>R<sub>4</sub> = ring formed through a CH<sub>2</sub>CH<sub>2</sub> linkage; or R<sub>2</sub> = Me; or R<sub>3</sub> = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; or R<sub>4</sub> = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; R<sub>5</sub> and R<sub>6</sub> = independently H, NO<sub>2</sub>, NH<sub>2</sub>, NHCOH, NHCOCH<sub>3</sub>, NHSO<sub>2</sub>CH<sub>3</sub>, or (un)substituted CH<sub>2</sub>NH-(hetero)alkyl or CH<sub>2</sub>NH-heterocyclyl; one of R<sub>7</sub> or R<sub>8</sub> = CHR<sub>10</sub>CONHOH; one of R<sub>7</sub> or R<sub>8</sub> = (un)substituted (hetero)alkyl, (alkyl)heterocyclyl, or alkylaryl; R<sub>9</sub> and R<sub>10</sub> = independently H or (un)substituted (hetero)alkyl, (alkyl)heterocyclyl, or alkylaryl] were prepared as peptide deformylase (Fe-PDF) inhibitors for treating various bacterial infections. For example, 3-pyrrolidinol was added to tert-Bu (R)-(2-pentyl)succinate mono(N-hydroxysuccinimide) ester to give the amide (68%). Treatment with 20% TFA/DCM, followed by MeOH, benzene, and TMSN<sub>2</sub> in hexanes, to afford the Me ester (90%). The

pyrrolidinol was coupled with 4-methoxyphenylisocyanate and the ester converted to the hydroxamic acid (IV) using  $\text{NH}_2\text{OH}\cdot\text{HCl}$ . The latter inhibited *E. coli* Fe-PDF with  $\text{IC}_{50}$  of 9 nM and showed selectivity for Fe-PDF vs. thermolysin with a selectivity index of 30,000. Thus, I, II, and III are useful as antibiotics against a broad range of infectious disease in animals and humans.

IT 409130-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide deformylase inhibitor; preparation of hydroxamic acid derivs. of peptides and peptidomimetics as peptide deformylase inhibitors for treatment of infectious diseases)

RN 409130-54-7 CAPLUS

CN 3-Pyrrolidineacetamide, 3-butyl-N-hydroxy-1-[(1S)-2-methyl-1-(1-pyrrolidinylcarbonyl)propyl]-2-oxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

